Learn how AI is transforming predictions of drug-induced liver injury and aiding drug development for safer therapeutics.

N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, today highlighted a ...

Illumina launched the Billion Cell Atlas to train AI on one billion single cells. AstraZeneca, Merck and Lilly are founding ...

The Billion Cell Atlas, backed by Eli Lilly, MSD and AstraZeneca, maps mechanisms to support informed drug discovery and ...

AI across the pharmaceutical ecosystem. The Illumina Billion Cell Atlas is the first tranche of its program to build a 5 billion cell atlas over three years, and will be the most comprehensive map of ...

A new study published in Ecology Letters has uncovered the mechanisms underlying plant community assembly and biodiversity ...

Illumina unveiled the Billion Cell Atlas, a large‑scale genetic perturbation dataset built with pharma partners to advance AI‑powered drug discovery, target validation, and disease biology.

Machine learning models reveal that histone marks are predictive of gene expression across human cell types and highlight important nuances between natural control and the effects of CRISPR-Cas9-based ...

AI Impact explores why AI security has outgrown human oversight, plus pricing gains, health care insight and key AI moves in ...

Cancer immunity and immunotherapy research increasingly recognizes that chronic inflammation is a major driver of tumorigenesis, yet the complex and dynamic ...